Findings

What do systematic reviews say?

4 questions · 4 findings · 1 reviews · Hepato-Biliary

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 3 · 75%Low 0 · 0%Moderate 1 · 25%High 0 · 0%

Adverse events · patients with primary biliary cirrhosis.

It is very uncertain whether bezafibrate changes adverse events compared with ursodeoxycholic acid (very low certainty).

1 finding from 1 review

Bezafibrate for primary biliary cirrhosis 2012 · Cochrane Headline outcomes only
RR 6.19 [0.31, 122.05]
2 studies · 69 participants
Very low

Alkaline phosphatase · patients with primary biliary cirrhosis.

1 finding from 1 review

Bezafibrate for primary biliary cirrhosis 2012 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 48 participants
Moderate

All‐cause mortality · patients with primary biliary cirrhosis.

It is very uncertain whether bezafibrate changes all‐cause mortality compared with ursodeoxycholic acid (very low certainty).

1 finding from 1 review

Bezafibrate for primary biliary cirrhosis 2012 · Cochrane Headline outcomes only
RD 0
2 studies · 69 participants
Very low

Liver morbidity · patients with primary biliary cirrhosis.

It is very uncertain whether bezafibrate changes liver morbidity compared with ursodeoxycholic acid (very low certainty).

1 finding from 1 review

Bezafibrate for primary biliary cirrhosis 2012 · Cochrane Headline outcomes only
RD 0
2 studies · 69 participants
Very low